What Will Happen to Regeneron Pharmaceuticals Inc Next? The Stock Just Had Huge Bearish Options Activity

 What Will Happen to Regeneron Pharmaceuticals Inc Next? The Stock Just Had Huge Bearish Options Activity

In today’s session Regeneron Pharmaceuticals Inc (REGN) recorded an unusually high (612) contracts volume of put trades. Someone, most probably a professional was a very active buyer of the October, 2016 put, expecting serious REGN decrease. With 612 contracts traded and 1444 open interest for the Oct, 16 contract, it seems this is a quite bearish bet. The option with symbol: REGN161021P00350000 closed last at: $1.1 or 8.3% down. About 139,582 shares traded hands. Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has declined 0.13% since March 15, 2016 and is downtrending. It has underperformed by 5.62% the S&P500.

Analysts await Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to report earnings on November, 2. They expect $2.27 earnings per share, down 12.36% or $0.32 from last year’s $2.59 per share. REGN’s profit will be $235.83M for 40.79 P/E if the $2.27 EPS becomes a reality. After $2.11 actual earnings per share reported by Regeneron Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 7.58% EPS growth.

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Ratings Coverage

Out of 19 analysts covering Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), 9 rate it a “Buy”, 1 “Sell”, while 9 “Hold”. This means 47% are positive. Regeneron Pharmaceuticals Inc. has been the topic of 40 analyst reports since July 28, 2015 according to StockzIntelligence Inc. Northland Capital initiated Regeneron Pharmaceuticals Inc (NASDAQ:REGN) rating on Wednesday, July 22. Northland Capital has “Market Perform” rating and $560 price target. UBS upgraded the shares of REGN in a report on Monday, September 7 to “Buy” rating. The rating was maintained by Chardan Capital Markets with “Buy” on Tuesday, August 4. The stock has “Outperform” rating given by RBC Capital Markets on Monday, July 27. Chardan Capital Markets downgraded the shares of REGN in a report on Wednesday, March 16 to “Sell” rating. Robert W. Baird downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Friday, August 5 to “Neutral” rating. Leerink Swann maintained it with “Outperform” rating and $630 target price in Monday, August 3 report. UBS maintained it with “Sell” rating and $565 target price in Wednesday, August 5 report. As per Wednesday, August 5, the company rating was maintained by Bernstein. Roth Capital upgraded the shares of REGN in a report on Tuesday, January 19 to “Buy” rating.

According to Zacks Investment Research, “Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Regeneron’s platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)”

Insitutional Activity: The institutional sentiment increased to 1.19 in Q2 2016. Its up 0.44, from 0.75 in 2016Q1. The ratio is positive, as 51 funds sold all Regeneron Pharmaceuticals Inc shares owned while 154 reduced positions. 50 funds bought stakes while 193 increased positions. They now own 70.88 million shares or 9.49% less from 78.30 million shares in 2016Q1.
British Columbia Inv Mgmt holds 0.13% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 43,093 shares. Bokf Na has 8,690 shares for 0.11% of their US portfolio. Winslow Cap Llc holds 835,437 shares or 1.19% of its portfolio. Advisory Services Networks Ltd Llc last reported 332 shares in the company. State Treasurer State Of Michigan, a Michigan-based fund reported 115,100 shares. Liberty Mutual Grp Inc Asset Mgmt Inc holds 0.07% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 5,618 shares. First Lp holds 86,900 shares or 0.1% of its portfolio. Architects accumulated 28 shares or 0% of the stock. Art Advsr Ltd Company accumulated 0.23% or 13,088 shares. Sivik Global Limited Liability Corp holds 1.74% of its portfolio in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) for 10,000 shares. Peak6 L P has 0.04% invested in the company for 13,072 shares. Valley Natl Advisers reported 15 shares or 0% of all its holdings. Blackrock Japan Ltd owns 97,600 shares or 0.12% of their US portfolio. Marshall Wace Ltd Liability Partnership owns 20,895 shares or 0.06% of their US portfolio. Analytic Invsts Limited Co reported 29,158 shares or 0.12% of all its holdings.

Insider Transactions: Since May 17, 2016, the stock had 1 buying transaction, and 3 selling transactions for $20.55 million net activity. Sanofi had bought 64,731 shares worth $23.55M. 2,125 shares were sold by GOLDSTEIN JOSEPH L, worth $903,125 on Friday, July 29. RYAN ARTHUR F sold $396,640 worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Tuesday, May 24. Shares for $1.70M were sold by Van Plew Daniel P on Tuesday, May 17.

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The company has a market cap of $38.48 billion. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. It has a 57.82 P/E ratio. It commercializes medicines for eye diseases, high low-density lipoprotein cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases.

REGN Company Profile

Regeneron Pharmaceuticals, Inc., incorporated on January 11, 1988, is a biopharmaceutical firm that discovers, invents, develops, makes and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions. The Firm commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol and a rare inflammatory condition, and has product candidates in development in other areas of unmet medical need, including oncology, rheumatoid arthritis (RA), asthma, atopic dermatitis, pain and infectious diseases. The Company’s marketed products include EYLEA (aflibercept) injection, Praluent (alirocumab) Injection and ARCALYST (rilonacept) injection for subcutaneous use. The Firm has over 10 product candidates in clinical development. These consist of Trap clinical programs and over 10 human monoclonal antibody product candidates. The Firm has generated each of the antibodies using its VelocImmune technology. The Company’s ARCALYST (rilonacept) Injection for subcutaneous Use is available in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children over 12 year.

More notable recent Regeneron Pharmaceuticals Inc (NASDAQ:REGN) news were published by: Fool.com which released: “Better Buy: Regeneron Pharmaceuticals, Inc. vs. Roche Holding AG” on October 13, 2016, also Fool.com with their article: “Is Another Blockbuster Drug on the Way for Regeneron Pharmaceuticals, Inc.?” published on October 10, 2016, Fool.com published: “Why Investors Are Paying a Premium for Regeneron Pharmaceuticals, Inc.” on September 29, 2016. More interesting news about Regeneron Pharmaceuticals Inc (NASDAQ:REGN) were released by: Prnewswire.com and their article: “How These Biotech Stocks are Faring? — Biogen, Juno Therapeutics, Regeneron …” published on October 18, 2016 as well as Profitconfidential.com‘s news article titled: “Regeneron Pharmaceuticals Inc: 40%+ Returns if REGN Stock Does THIS” with publication date: September 23, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment